Oregon § 353.485 Oregon Psychiatric Access Line program

Oregon Statutes

§ 353.485 — Oregon Psychiatric Access Line program

Oregon § 353.485

Vol.9

Title 30Education and Culture

Ch. 353Oregon Health and Science University

This text of Oregon § 353.485 (Oregon Psychiatric Access Line program) is published on Counsel Stack Legal Research, covering Oregon primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Or. Rev. Stat. § 353.485 (2026).

Text

(1)There is established the Oregon Psychiatric Access Line program in the Oregon Health and Science University.

(2)The Oregon Psychiatric Access Line program shall provide telephone or electronic real-time psychiatric consultations, from 9 a.m. to 5 p.m. on all business days, to primary care providers who care for patients with mental health disorders.

(3)Psychiatrists providing advice to primary care providers through the Oregon Psychiatric Access Line program regarding prescription drug treatment options shall be informed by any applicable guidelines:

(a)In the Practitioner-Managed Prescription Drug Plan adopted by the Oregon Health Authority under ORS 414.334; or

(b)Recommended by the Pharmacy and Therapeutics Committee established by ORS 414.353.

Free access — add to your briefcase to read the full text and ask questions with AI

(1) There is established the Oregon Psychiatric Access Line program in the Oregon Health and Science University.
(2) The Oregon Psychiatric Access Line program shall provide telephone or electronic real-time psychiatric consultations, from 9 a.m. to 5 p.m. on all business days, to primary care providers who care for patients with mental health disorders.
(3) Psychiatrists providing advice to primary care providers through the Oregon Psychiatric Access Line program regarding prescription drug treatment options shall be informed by any applicable guidelines:
(a) In the Practitioner-Managed Prescription Drug Plan adopted by the Oregon Health Authority under ORS 414.334; or
(b) Recommended by the Pharmacy and Therapeutics Committee established by ORS 414.353.